TrialPanorama/TrialPanorama-database huggingface dataset:
Study: 24572041

Group type: EXPERIMENTAL
Intervention: Lupin kernel fiber (LF) 25-g/d
Number of subjects: 60
Study: 21923659

Group type: EXPERIMENTAL
Intervention: Low fluence high repetition rate 810 nm diode laser
Number of subjects: 49

Group type: COMPARATOR
Intervention: High fluence low repetition rate 1064 nm Nd:YAG laser
Number of subjects: 49
Study: 20107202

Group type: EXPERIMENTAL
Intervention: LRPT 50 mg
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: LRPT 600 mg
Number of subjects: 0

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Moxifloxacin 400 mg
Number of subjects: 0
Study: 17352635

Group type: EXPERIMENTAL
Intervention: Laser therapy (7 joules/2 min) over the carpal tunnel area, 41 patients
Number of subjects: 81

Group type: COMPARATOR
Intervention: Placebo laser therapy, 40 patients
Number of subjects: 81
Study: 15142298

Group type: EXPERIMENTAL
Intervention: Emotional Stroop task with asthma symptom words
Number of subjects: 3

Group type: COMPARATOR
Intervention: Emotional Stroop task with general negative words
Number of subjects: 3

Group type: EXPERIMENTAL
Intervention: Self-reported adherence levels
Number of subjects: 3
Study: 11524195

Group type: EXPERIMENTAL
Intervention: Ketorolac tromethamine 0.5%
Number of subjects: 36

Group type: COMPARATOR
Intervention: Rimexolone 1%
Number of subjects: 36
Study: 9810742

Group type: EXPERIMENTAL
Intervention: Experimental design (e.g. randomized clinical trial)
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Non-experimental designs (case series analysis, cohort and case control studies)
Number of subjects: 0
Study: 7824087

Group type: EXPERIMENTAL
Intervention: Erythromycin (3.5 mg/kg bolus injection)
Number of subjects: 22

Group type: COMPARATOR
Intervention: Standard meal
Number of subjects: 22
Study: 3277488

Group type: EXPERIMENTAL
Intervention: Isosorbide dinitrate ointment (100 mg tid)
Number of subjects: 30

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 30
Study: 29925328

Group type: EXPERIMENTAL
Intervention: Gabapentin oral solution (5 mg/kg in 5 ml strawberry juice)
Number of subjects: 70

Group type: COMPARATOR
Intervention: Placebo (5 ml of oral strawberry juice)
Number of subjects: 70
Study: 29231406

Group type: EXPERIMENTAL
Intervention: Lateral position group
Number of subjects: 76

Group type: COMPARATOR
Intervention: Prone position group
Number of subjects: 76
Study: 24527598

Group type: EXPERIMENTAL
Intervention: Elastic taping for 5 days with therapeutic stretch
Number of subjects: 0

Group type: COMPARATOR
Intervention: Placebo taping without therapeutic stretch
Number of subjects: 0
Study: 23536312

Group type: EXPERIMENTAL
Intervention: True suprasensory stimulation
Number of subjects: 11

Group type: COMPARATOR
Intervention: Sham stimulation
Number of subjects: 11
Study: 20223573

Group type: EXPERIMENTAL
Intervention: 4% articaine HCl with 1:100,000 epinephrine
Number of subjects: 30

Group type: EXPERIMENTAL
Intervention: 4% articaine HCl with 1:200,000 epinephrine
Number of subjects: 30
Study: 18768528

Group type: EXPERIMENTAL
Intervention: Subcutaneous bortezomib (1.3 mg/m2, days 1, 4, 8, 11; eight 21‐day cycles)
Number of subjects: 24

Group type: COMPARATOR
Intervention: Intravenous bortezomib (1.3 mg/m2, days 1, 4, 8, 11; eight 21‐day cycles)
Number of subjects: 24
Study: 16864147

Group type: EXPERIMENTAL
Intervention: Raloxifene 60 mg/day for 6 months
Number of subjects: 40
Study: 15298978

Group type: EXPERIMENTAL
Intervention: Day 3 transfer
Number of subjects: 460

Group type: COMPARATOR
Intervention: Day 5 transfer
Number of subjects: 460
Study: 11930704

Group type: EXPERIMENTAL
Intervention: Inhaled Beclomethasone dipropionate (BDP) 200 micrograms/d
Number of subjects: 30

Group type: EXPERIMENTAL
Intervention: Inhaled Beclomethasone dipropionate (BDP) 400 micrograms/d
Number of subjects: 30

Group type: COMPARATOR
Intervention: Inhaled placebo
Number of subjects: 30
Study: 9773137

Group type: EXPERIMENTAL
Intervention: Enalaprilat 30 micrograms.kg-1
Number of subjects: 38

Group type: COMPARATOR
Intervention: NaCl 0.9% (Control)
Number of subjects: 38
Study: 7880660

Group type: EXPERIMENTAL
Intervention: Transdermal hyoscine
Number of subjects: 60

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 60
Study: 3345619

Group type: EXPERIMENTAL
Intervention: 0.5 mg alprazolam plus saline infusion
Number of subjects: 4

Group type: EXPERIMENTAL
Intervention: 2.0 mg alprazolam plus saline
Number of subjects: 4

Group type: EXPERIMENTAL
Intervention: 1.0 mg plus 72 micrograms alprazolam/hr for a total dose of 1.576 mg in 8 hours
Number of subjects: 4

Group type: COMPARATOR
Intervention: Placebo (50% propylene glycol injection followed by saline infusion)
Number of subjects: 4
Study: 31782027

Group type: EXPERIMENTAL
Intervention: Emotional Overeating Questionnaire (EOQ)
Number of subjects: 314
Study: 30638420

Group type: EXPERIMENTAL
Intervention: Daily consumption of commercial pasteurized orange juice for 2 months
Number of subjects: 10
Study: 28351028

Group type: EXPERIMENTAL
Intervention: Higher protein (HP) formula
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Lower protein (LP) formula
Number of subjects: 0

Group type: COMPARATOR
Intervention: Breastfed (BF) infants
Number of subjects: 0
Study: 26531197

Group type: EXPERIMENTAL
Intervention: Proctored, proficiency‐based, virtual reality robotic suturing curriculum using the da Vinci(®) Skills Simulator™
Number of subjects: 27

Group type: COMPARATOR
Intervention: Control group (non-participation in training)
Number of subjects: 27
Study: 23796193

Group type: EXPERIMENTAL
Intervention: Apixaban
Number of subjects: 0

Group type: COMPARATOR
Intervention: Warfarin
Number of subjects: 0
Study: 22120029

Group type: EXPERIMENTAL
Intervention: Meaningful Task Specific Training (MTST)
Number of subjects: 71
Study: 19720642

Group type: EXPERIMENTAL
Intervention: Biodegradable polymer DES (rapamycin-eluting)
Number of subjects: 2603

Group type: COMPARATOR
Intervention: Permanent polymer DES (rapamycin-eluting, Cypher; or everolimus-eluting, Xience)
Number of subjects: 2603

Group type: EXPERIMENTAL
Intervention: Biodegradable polymer DES
Number of subjects: 2603

Group type: COMPARATOR
Intervention: Permanent polymer DES
Number of subjects: 2603
Study: 17045888

Group type: EXPERIMENTAL
Intervention: Atorvastatin (40 mg/day)
Number of subjects: 76

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 76
Study: 12580655

Group type: EXPERIMENTAL
Intervention: Ribose supplementation (32 g, 4 x 8-g doses)
Number of subjects: 0

Group type: COMPARATOR
Intervention: Cellulose (placebo)
Number of subjects: 0
Study: 10958029

Group type: EXPERIMENTAL
Intervention: Hormone replacement therapy (HRT)
Number of subjects: 268
Study: 9076407

Group type: EXPERIMENTAL
Intervention: One additional egg per day
Number of subjects: 32

Group type: COMPARATOR
Intervention: Control group (no additional egg)
Number of subjects: 32
Study: 8449014

Group type: EXPERIMENTAL
Intervention: Ortho 7/7/7
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Triphasil
Number of subjects: 0

Group type: COMPARATOR
Intervention: Control
Number of subjects: 0
Study: 3513540

Group type: EXPERIMENTAL
Intervention: Theo-Dur
Number of subjects: 20

Group type: EXPERIMENTAL
Intervention: Uniphyl
Number of subjects: 20

Group type: EXPERIMENTAL
Intervention: Serum theophylline levels
Number of subjects: 20

Group type: EXPERIMENTAL
Intervention: Pulmonary function tests (PFTs)
Number of subjects: 20
Study: 30411316

Group type: EXPERIMENTAL
Intervention: Supervised exercise training
Number of subjects: 140

Group type: COMPARATOR
Intervention: Nonsupervised exercise training
Number of subjects: 140
Study: 26210303

Group type: EXPERIMENTAL
Intervention: Active tVNS (daily active stimulation of the left auricle for 26 weeks)
Number of subjects: 20

Group type: COMPARATOR
Intervention: Sham tVNS (daily sham stimulation for 12 weeks followed by 14 weeks of active stimulation)
Number of subjects: 20
Study: 24468255

Group type: EXPERIMENTAL
Intervention: MK-7243 (2,800 BAU Phleum pratense)
Number of subjects: 1501

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 1501
Study: 22024002

Group type: EXPERIMENTAL
Intervention: Another SSRI
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Venlafaxine
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Another SSRI + cognitive behavior therapy (CBT)
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Venlafaxine + CBT
Number of subjects: 0

Group type: COMPARATOR
Intervention: Control group (school difficulties)
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Adequate depression response
Number of subjects: 0
Study: 19729392

Group type: EXPERIMENTAL
Intervention: Conjugated equine estrogens (CEE)-based therapies
Number of subjects: 1403

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 1403
Study: 17664205

Group type: EXPERIMENTAL
Intervention: Tranexamic acid (10 mg x kg(‐1) bolus prior to sternotomy, followed by 1 mg x kg(‐1) x hr(‐1) infusion)
Number of subjects: 222

Group type: COMPARATOR
Intervention: Saline (control group)
Number of subjects: 222

Group type: EXPERIMENTAL
Intervention: Tranexamic acid
Number of subjects: 222
Study: 15377312

Group type: EXPERIMENTAL
Intervention: Radiofrequency neurotomy of facet joints C2-C6 ipsilateral to the pain
Number of subjects: 12

Group type: COMPARATOR
Intervention: Sham treatment
Number of subjects: 12
Study: 11432472

Group type: EXPERIMENTAL
Intervention: Direct infusion
Number of subjects: 60

Group type: EXPERIMENTAL
Intervention: Ultrafiltration
Number of subjects: 60

Group type: COMPARATOR
Intervention: Centrifugation
Number of subjects: 60
Study: 9683306

Group type: EXPERIMENTAL
Intervention: Tamoxifen (20 mg day(-1))
Number of subjects: 463

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 463

Group type: EXPERIMENTAL
Intervention: Norethisterone (2.5 mg day(-1) for 21 days out of 28 for three cycles)
Number of subjects: 463
Study: 7851255

Group type: EXPERIMENTAL
Intervention: two-pump protocol
Number of subjects: 58

Group type: COMPARATOR
Intervention: GIK infusion
Number of subjects: 58
Study: 3387033

Group type: EXPERIMENTAL
Intervention: High-dose dexamethasone and high-dose metoclopramide (regimen A)
Number of subjects: 28

Group type: COMPARATOR
Intervention: High-dose dexamethasone and sulpiride (regimen B)
Number of subjects: 28
Study: 31524116

Group type: EXPERIMENTAL
Intervention: 8-week low-fat diet (<20% energy from fat)
Number of subjects: 0

Group type: COMPARATOR
Intervention: 8-week high-fat diet (>35% energy from fat)
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Low-fat diet
Number of subjects: 0
Study: 27720403

Group type: EXPERIMENTAL
Intervention: 25 μg calcitriol
Number of subjects: 120

Group type: EXPERIMENTAL
Intervention: 500 mg calcium carbonate + 25 μg calcitriol
Number of subjects: 120

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 120
Study: 25825344

Group type: EXPERIMENTAL
Intervention: Single-phase acquisition protocol
Number of subjects: 140

Group type: COMPARATOR
Intervention: Multi-phase acquisition protocol
Number of subjects: 140
Study: 22886138

Group type: EXPERIMENTAL
Intervention: Polidocanol (POL) micro-foam injection
Number of subjects: 90

Group type: COMPARATOR
Intervention: Nd:YAG laser alone
Number of subjects: 90

Group type: EXPERIMENTAL
Intervention: Laser after POL injection
Number of subjects: 90
Study: 21325298

Group type: EXPERIMENTAL
Intervention: Panel of CA 19‐9, ICAM‐1, and OPG
Number of subjects: 333

Group type: EXPERIMENTAL
Intervention: Panel of CA 19‐9, CEA, and TIMP‐1
Number of subjects: 333

Group type: EXPERIMENTAL
Intervention: CA19‐9, ICAM‐1, OPG panel
Number of subjects: 333
Study: 19281731

Group type: EXPERIMENTAL
Intervention: Losectil DR (Test)
Number of subjects: 24

Group type: COMPARATOR
Intervention: LOSEC (Reference)
Number of subjects: 24
Study: 17885932

Group type: EXPERIMENTAL
Intervention: High trihalomethanes (TTHM) concentrations in drinking water
Number of subjects: 65

Group type: COMPARATOR
Intervention: Lowest trihalomethanes (TTHM) concentrations in drinking water
Number of subjects: 65
Study: 14979860

Group type: EXPERIMENTAL
Intervention: Higher stress in female and young patients
Number of subjects: 322

Group type: EXPERIMENTAL
Intervention: Moderate income, congestive heart failure, high social conflict, low social support, negative coping style
Number of subjects: 322
Study: 15265408

Group type: EXPERIMENTAL
Intervention: Rofecoxib 25 mg (group RE, n = 15)
Number of subjects: 30

Group type: COMPARATOR
Intervention: Placebo (group E, n = 15)
Number of subjects: 30
Study: 10421125

Group type: EXPERIMENTAL
Intervention: Enflurane administration (0.5% to 2%) for 5 minutes
Number of subjects: 22

Group type: COMPARATOR
Intervention: Control group (no enflurane administration)
Number of subjects: 22
Study: 7554976

Group type: EXPERIMENTAL
Intervention: Daily administration of contraceptive pill for 21 days with a seven-day interruption (intermittent use)
Number of subjects: 900

Group type: COMPARATOR
Intervention: Daily administration of contraceptive pill without interruption (continuous use)
Number of subjects: 900

Group type: EXPERIMENTAL
Intervention: Both groups (intermittent and continuous use)
Number of subjects: 900
Study: 2404917

Group type: EXPERIMENTAL
Intervention: Radiation field size: 5 x 5 cm2 (Group A)
Number of subjects: 87

Group type: EXPERIMENTAL
Intervention: Radiation field size: 6 x 6 cm2 (Group B)
Number of subjects: 87

Group type: COMPARATOR
Intervention: Historical control
Number of subjects: 87

Group type: EXPERIMENTAL
Intervention: Group B (6 x 6 cm2)
Number of subjects: 87
Study: 6158370

Group type: EXPERIMENTAL
Intervention: Vinblastine 0.4 mg/kg every three weeks for four courses
Number of subjects: 78

Group type: COMPARATOR
Intervention: Vinblastine 0.3 mg/kg every three weeks for four courses
Number of subjects: 78

Group type: EXPERIMENTAL
Intervention: Vinblastine 0.2 mg/kg plus Adriamycin 50 mg/M2 every three weeks for four courses
Number of subjects: 78

Group type: EXPERIMENTAL
Intervention: Maintenance therapy with vinblastine 0.3 mg/kg once a month for 20 months
Number of subjects: 78

Group type: EXPERIMENTAL
Intervention: Overall treatment
Number of subjects: 78

Group type: EXPERIMENTAL
Intervention: Comparison of vinblastine dosages
Number of subjects: 78
Study: 31240397

Group type: EXPERIMENTAL
Intervention: Upper-body resistance training (UB)
Number of subjects: 40

Group type: EXPERIMENTAL
Intervention: Lower-body resistance training (LB)
Number of subjects: 40

Group type: EXPERIMENTAL
Intervention: Combined resistance training (UB + LB)
Number of subjects: 40

Group type: COMPARATOR
Intervention: Control (C)
Number of subjects: 40
Study: 29407250

Group type: EXPERIMENTAL
Intervention: Pediatric orthopedists (Group A)
Number of subjects: 90

Group type: COMPARATOR
Intervention: Non-pediatric orthopedists (Group B)
Number of subjects: 90

Group type: EXPERIMENTAL
Intervention: Both groups (A and B)
Number of subjects: 90
Study: 28115877

Group type: EXPERIMENTAL
Intervention: Intrathecal Morphine (Group M)
Number of subjects: 50

Group type: COMPARATOR
Intervention: Intrathecal Fentanyl (Group F)
Number of subjects: 50
Study: 24581050

Group type: EXPERIMENTAL
Intervention: Tailor-made notched music training (TMNMT) for two hours a day for three months
Number of subjects: 100

Group type: COMPARATOR
Intervention: Control group not specified
Number of subjects: 100
Study: 22190273

Group type: EXPERIMENTAL
Intervention: Calcium plus vitamin D supplementation (1,000 mg calcium carbonate plus 400 IU vitamin D(3) daily)
Number of subjects: 32435

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 32435
Study: 19685190

Group type: EXPERIMENTAL
Intervention: Kenkou‐tatsujin (KTP) group (KTPG)
Number of subjects: 51

Group type: COMPARATOR
Intervention: Control group (CG)
Number of subjects: 51

Group type: EXPERIMENTAL
Intervention: KTPG
Number of subjects: 51

Group type: COMPARATOR
Intervention: CG
Number of subjects: 51
Study: 17340636

Group type: EXPERIMENTAL
Intervention: S1 (gadolinium as oral tagging agent and a gadolinium-water mixture for rectal filling)
Number of subjects: 45

Group type: COMPARATOR
Intervention: S2 (oral barium and water rectally)
Number of subjects: 45

Group type: EXPERIMENTAL
Intervention: S3 (oral barium and air rectally)
Number of subjects: 45
Study: 16336763

Group type: EXPERIMENTAL
Intervention: Two protease inhibitors (saquinavir + nelfinavir)
Number of subjects: 30

Group type: COMPARATOR
Intervention: One protease inhibitor (saquinavir soft gel capsule)
Number of subjects: 30
Study: 12014487

Group type: EXPERIMENTAL
Intervention: Precision tinted lenses
Number of subjects: 21

Group type: COMPARATOR
Intervention: Control tinted lenses
Number of subjects: 21
Study: 10582199

Group type: EXPERIMENTAL
Intervention: Sublingual immunotherapy
Number of subjects: 39

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 39
Study: 7602675

Group type: EXPERIMENTAL
Intervention: Classical uvulopalatopharyngoplasty (UPPP) technique
Number of subjects: 68

Group type: COMPARATOR
Intervention: Modified 'extended UPPP technique' (bilateral resection of the palatopharyngeal muscles)
Number of subjects: 68
Study: 28829051

Group type: EXPERIMENTAL
Intervention: Dopamine transporter (DAT) availability assessed with PET and [11C]PE2I
Number of subjects: 27

Group type: EXPERIMENTAL
Intervention: Reward-related neural response assessed using fMRI with a modified Monetary Incentive Delay task
Number of subjects: 27
Study: 28445374

Group type: EXPERIMENTAL
Intervention: External splint fixation
Number of subjects: 0

Group type: COMPARATOR
Intervention: Coronal flap plate fixation
Number of subjects: 0

Group type: COMPARATOR
Intervention: No surgery
Number of subjects: 0

Group type: COMPARATOR
Intervention: Intraoral approach (no fixation)
Number of subjects: 0

Group type: COMPARATOR
Intervention: Temporal approach (no fixation)
Number of subjects: 0
Study: 26289949

Group type: COMPARATOR
Intervention: Artemether-lumefantrine (AL)
Number of subjects: 680

Group type: EXPERIMENTAL
Intervention: Artesunate-amodiaquine (ASAQ)
Number of subjects: 680
Study: 24129868

Group type: EXPERIMENTAL
Intervention: Web-based Basic Skin Cancer Triage (BSCT) course
Number of subjects: 57

Group type: COMPARATOR
Intervention: Control web-based course on weight assessment
Number of subjects: 57
Study: 21158502

Group type: EXPERIMENTAL
Intervention: Non-words (NWs)
Number of subjects: 4

Group type: COMPARATOR
Intervention: Real words (RWs)
Number of subjects: 4
Study: 18205965

Group type: EXPERIMENTAL
Intervention: Internet-based cognitive behavioural therapy (CBT)
Number of subjects: 301

Group type: COMPARATOR
Intervention: Waiting-list control group
Number of subjects: 301

Group type: EXPERIMENTAL
Intervention: Group CBT (Lewinsohn's Coping with Depression Course)
Number of subjects: 301
Study: 16573870

Group type: EXPERIMENTAL
Intervention: Not available
Number of subjects: 0
Study: 14626395

Group type: EXPERIMENTAL
Intervention: Preincisional periportal infiltration with 20 mL of ropivacaine (10 mg/mL)
Number of subjects: 190

Group type: COMPARATOR
Intervention: Saline (control group)
Number of subjects: 190
Study: 10711915

Group type: EXPERIMENTAL
Intervention: Nortriptyline maintenance therapy (plasma levels 60-150 ng/mL) for up to 2 years
Number of subjects: 58

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 58
Study: 9352864

Group type: EXPERIMENTAL
Intervention: Growth hormone (0.25 IU/kg body wt)
Number of subjects: 20

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 20
Study: 8412261

Group type: EXPERIMENTAL
Intervention: Cefamandole
Number of subjects: 1641

Group type: EXPERIMENTAL
Intervention: Cefazolin
Number of subjects: 1641

Group type: EXPERIMENTAL
Intervention: Cefuroxime
Number of subjects: 1641

Group type: COMPARATOR
Intervention: Control (no specific control mentioned)
Number of subjects: 1641
Study: 3082103

Group type: EXPERIMENTAL
Intervention: Netilmicin plus azlocillin
Number of subjects: 42

Group type: COMPARATOR
Intervention: Netilmicin plus ticarcillin
Number of subjects: 42

Group type: EXPERIMENTAL
Intervention: Both regimens
Number of subjects: 42
Study: 31442298

Group type: EXPERIMENTAL
Intervention: Ticagrelor-based DAPT
Number of subjects: 44

Group type: EXPERIMENTAL
Intervention: Ticagrelor-monotherapy
Number of subjects: 44
Study: 29041823

Group type: EXPERIMENTAL
Intervention: Tactile cues to the hip muscles
Number of subjects: 10

Group type: EXPERIMENTAL
Intervention: Verbal cues
Number of subjects: 10

Group type: EXPERIMENTAL
Intervention: Tactile cues
Number of subjects: 10

Group type: COMPARATOR
Intervention: Control (no cue)
Number of subjects: 10
Study: 29095942

Group type: EXPERIMENTAL
Intervention: Vitamin E therapy
Number of subjects: 314

Group type: EXPERIMENTAL
Intervention: Pioglitazone
Number of subjects: 314

Group type: EXPERIMENTAL
Intervention: Metformin
Number of subjects: 314

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 314

Group type: EXPERIMENTAL
Intervention: Overall analysis
Number of subjects: 314

Group type: EXPERIMENTAL
Intervention: Longitudinal analysis
Number of subjects: 314
Study: 25578146

Group type: EXPERIMENTAL
Intervention: Screening group (10,411 women)
Number of subjects: 20904

Group type: COMPARATOR
Intervention: Control group (10,949 women)
Number of subjects: 20904

Group type: EXPERIMENTAL
Intervention: Screening group
Number of subjects: 20904

Group type: COMPARATOR
Intervention: Control group
Number of subjects: 20904
Study: 22886852

Group type: EXPERIMENTAL
Intervention: Atropine/scopolamine mixture at 12.10/9.50 µg kg(‐1) body mass (BM)
Number of subjects: 20

Group type: EXPERIMENTAL
Intervention: Atropine/scopolamine mixture at 0.37/0.29 and 1.22/0.95 µg kg(‐1) BM
Number of subjects: 20

Group type: EXPERIMENTAL
Intervention: Atropine/scopolamine mixture at 0.12/0.10 µg kg(‐1) BM
Number of subjects: 20

Group type: COMPARATOR
Intervention: Atropine/scopolamine mixture (various doses)
Number of subjects: 20
Study: 21982669

Group type: EXPERIMENTAL
Intervention: Cardiac-derived biomarkers (subset of first 1,000 patients enrolled)
Number of subjects: 3847

Group type: EXPERIMENTAL
Intervention: Prior heart failure
Number of subjects: 3847

Group type: EXPERIMENTAL
Intervention: Age
Number of subjects: 3847

Group type: EXPERIMENTAL
Intervention: Log urine protein/creatinine ratio
Number of subjects: 3847

Group type: EXPERIMENTAL
Intervention: C-reactive protein ≥6.6 mg/L
Number of subjects: 3847

Group type: EXPERIMENTAL
Intervention: Abnormal electrocardiogram
Number of subjects: 3847

Group type: EXPERIMENTAL
Intervention: Cardiac-derived biomarkers
Number of subjects: 3847
Study: 18488436

Group type: EXPERIMENTAL
Intervention: Tiotropium 18 microg daily
Number of subjects: 91

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 91
Study: 16343498

Group type: EXPERIMENTAL
Intervention: Sublingual misoprostol 400 mcg
Number of subjects: 100

Group type: COMPARATOR
Intervention: Intravenous oxytocin infusion 20 units
Number of subjects: 100
Study: 14759306

Group type: EXPERIMENTAL
Intervention: Nonnutritive sucking (NNS)
Number of subjects: 38
Study: 11061198

Group type: COMPARATOR
Intervention: Active trans-femoral and trans-tibial amputees
Number of subjects: 18

Group type: COMPARATOR
Intervention: Intact limb ankle
Number of subjects: 18

Group type: COMPARATOR
Intervention: Intact limb knee
Number of subjects: 18

Group type: COMPARATOR
Intervention: Intact limb hip
Number of subjects: 18
Study: 8621132

Group type: EXPERIMENTAL
Intervention: Spironolactone (100 mg/d for 6 weeks)
Number of subjects: 20

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 20